Health comorbidities and cognition in 1948 patients with idiopathic Parkinson's disease

Parkinsonism and Related Disorders

Volumn 18, Issue 10, 2012, Pages 1073-1078

  Jones, J D ^a   Malaty, I ^a   Price, C C ^a   Okun, M S ^a   Bowers, D ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cardiovascular; Comorbidities; Neuropsychology; Parkinson's disease Parkinsonism; Prevalence

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTHRITIS; ARTICLE; COGNITION; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HEART DISEASE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC PARKINSON DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEMORY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; RECALL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SEMANTIC FLUENCY SCORE; SEMANTICS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; CARDIOVASCULAR DISEASES; COGNITION; COGNITION DISORDERS; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NEOPLASMS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREVALENCE; REGISTRIES; RISK FACTORS;

EID: 84870565333     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.06.004     Document Type: Article

References (30)

1. Alexander G.E., DeLong M.R., Strick P.L. Parallel Organization of Functionally segregated circuits linking Basal Ganglia and Cortex. Annual Review of Neuroscience 1986, 9(1):357-381.
2. Zgaljardic D.J., Borod J.C., Foldi N.S., Mattis P.J. A review of the coGnitive and behavioral sequelae of Parkinson's disease. Relationship to Frontostriatal Circuitry 2003, 16(4):193-210.
3. Aarsland D., Brønnick K., Larsen J.P., Tysnes O.B., Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009, 72(13):1121-1126.
4. Williams-Gray C.H., Evans J.R., Goris A., Foltynie T., Ban M., Robbins R., et al. The distinct cognitive syndromes of Parkinson's disease: 5 year followup of the CamPaIGN cohort. Brain 2009, 132(11):2958-2969.
5. Owen A.M., Sahakian B.J., Hodges J.R., Summers B.A., Polkey C.E., Robbins T.W. Dopamine-dependent fronto-striatal planning deficits in early Parkinson's disease. Neuropsychology 1995, 9:126-140.
6. Bohnen N.I., Kaufer D.I., Ivanco L.S., Koeppe R.S., Dais J.G., Mathis C.A., et al. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Archives of Neurology 2003, 60:1745-1748.
7. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G.L. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Movement Disorders 2008, 23:837-844.
8. Verdelho A., Madureira S., Ferro J.M., Basile A.M., Chabriat H., Erkinjuntti T., et al. Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 2007, 78:1325-1330.
9. Ruitenberg A., Skoog I., Ott A., Witteman J.C.M., van Harskamp F., Hofman A., et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Demen Geriatr Cogn Disord 2001, 12:33-39.
10. Bezerra D.C., Sharrett A.R., Matsushita K., Gottesman R.F., Shibata D., Mosley T.H., et al. Risk factors for lacune subtypes in the Atherosclerosis risk in Communities (ARIC) study. Neurology 2012, 78:102-108.
11. Kennedy K.M. Raz N.Aging, white matter, and cognition: differential effects of regional variations in diffusion properties on memory, executive functions, and speed. Neuropsychologia 2009, 47:916-927.
12. Price CC., Mitchell, S., Brumback, B., Tanner J, Schmalfuss I, Lamar M, et al. The Leukoaraiosis (LA) 25% threshold and the phenotypic expression of dementia. Neurology 2012, in press.
13. Haugarvoll K., Aarsland D., Wentzel-Larsen T., Larsen J.P. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurologica Scandinavica 2005, 112(6):386-390.
14. Slawek J., Wieczorek D., Dubaniewicz M., Lass P. The influence of vascular risk factors and hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol Neuorchir Pol 2008, 42(6):505-512.
15. Dalaker T.O., Larsen J.P., Dwyer M.G., Aarsland D., Beyer M.K., Alves G., et al. White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage 2009, 47:2083-2089.
16. Lee S.J., Kim J.S., Yoo J.Y., Song I.U., Kim B., Jung S.L., et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010, 24:227-233.
17. Beyer M.K., Aarsland D., Greve O.J., Larsen J.P. Visual rating of white matter hyperintensities in Parkinson's disease. Movement Disorders 2006, 23:223-229.
18. Nanhoe-Mahabier W., de Laat K., Visser J.E., Zijlmans J., de Leeuw F.E., Bloem B.R. Parkinson disease and comorbid cerebrovascular disease. Nature Reviews Neurology 2009, 5:533-541.
19. Okun M.S., Siderowf A., Nutt J.G., O'Conner G.T., Bloem B.R., Olmstead E.M., et al. Piloting the NPF data-driven quality improvement initiative. Parkinsonism & Related Disorders 2010, 16(8):517-521.
20. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal Neurology. Neurosurgery & Psychiatry 1992, 55(3):181-184.
21. Hoehn M., Yahr M. Parkinsonism: onset, progression, and mortality. Neurology 1967, 17:738-750.
22. Tombaugh T., Kozak J., Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 1999, 14(2):167-177.
23. Nasreddine Z.S., Phillips N.A., Bedirian V., Charbonneau S., Whitehead V., Collin I., et al. The Montreal Cognitive Assessment (MOCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005, 53:695-699.
24. Hays W.L. Statistics 1994, Cengage Learning, Clifton Park, NY. 5th ed.
25. Aronow W.S., Fleg J.L., Pepine C.J., Artinian N.T., Bakris G., Brown A., et al. Expert Consensus Documenta ACCF/AHA 2011 Expert Consensus Document oh Hypertension in the Elderly. J Am Soc Hypertension 2011, 5(4):259-352.
26. Raz N., Rodrigue K.M., Kennedy K.M., Acker J.D. Vascular health and longitudinal changes in brain and cognition in middle-aged and older adults. Neuropsychology 2007, 21:149-157.
27. Debette S., Seshadri S., Beiser A., Au R., Himali J.J., Palumbo C., et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011, 77(5):461-468.
28. Schmidt H., Zeginigg M., Wiltgen M., Himali J.J., Palumbo C., Wolf P.A., et al. Genetic variants of the NOTCH3 gene in the elderly and and magnetic resonance imaging correlates of age-related cerebral small vessel disease. Brain 2011, 134:3384-3397.
29. Wu W., Brickman A.M., Luchsinger J., Ferrazzano P., Pichiule P., Yoshita M., et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Annals of Neurology 2008, 64(6):698-706.
30. Choi S.A., Evidente V.G., Caviness J.N. Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with and without dementia?. Acta Neuopathol 2010, 119:147-149.